Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Frontline Ruxolitinib With De-Intensified HLH-94 for Adult Hemophagocytic Lymphohistiocytosis (HLH): A Multicenter, Single-Arm Phase 2 Study

NCT06160791 is registered in ClinicalTrials.gov with Jerry Lee, MD, MSc, MPhil as lead sponsor.

NCT NCT06160791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06160791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Frontline Ruxolitinib With De-Intensified HLH-94 for Adult Hemophagocytic Lymphohistiocytosis (HLH): A Multicenter, Single-Arm Phase 2 Study
Lead sponsor
Jerry Lee, MD, MSc, MPhil
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2024
Completion date
November 30, 2029
Enrollment
54 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hemophagocytic lymphohistiocytoses